Firms

Avego BioScience Capital

Avego BioScience Capital

avego.com

Avego BioScience Capital is Avego's venture investment strategy for biotechnology companies at pivotal stages of therapeutic development. Its stated focus is mid-to-late-stage ventures in neurology, oncology, immunology, ophthalmology and rare disease, across biologics, small molecules and cell and gene therapies. It favors evidence-backed proprietary technologies and experienced drug-development teams. Publicly verified professionals include partner Vishal Kapoor, managing director Eric Pham and principal Christy Kuo; Bala Venkataraman manages the general partner, and Alyssa Romano holds finance and compliance leadership roles. Investments include MapLight Therapeutics, CellCentric and Memento Medicines. SEC filings identify the original Avego Bioscience Capital, L.P. vehicle, formed in 2021, and Avego BioScience Capital Fund II, L.P., formed in 2026. These are distinct funds within the strategy.

Founded
—
Type
Venture capital

Funds2

  • Avego BioScience Capital Fund II, L.P.—

    Second Avego BioScience Capital venture fund, formed in Delaware in 2026. An April 6, 2026 SEC filing reported USD60 million sold to one investor, with the first sale April 1, 2026 and an indefinite offering amount. Memento Medicines' June 18, 2026 financing announcement confirms the strategy is investing from its second venture fund. No final close or final fund size is asserted.

  • Avego Bioscience Capital, L.P.—

    Original Avego BioScience Capital fund vehicle, formed in Delaware in 2021. A March 7, 2025 SEC amendment reported USD68,741,447 of interests sold to 18 investors and an indefinite offering amount. The first sale occurred January 12, 2021. The reported amount sold is retained as a filing snapshot, with no announced final fund size inferred.

Team

Operations and support

Alyssa RomanoAlyssa RomanoChief Financial Officer and Chief Compliance Officer
Bala VenkataramanBala VenkataramanManaging Member of the General Partner
Christy KuoChristy KuoPrincipal
Eric PhamEric PhamManaging Director
Vishal KapoorVishal KapoorPartner

Co-investing

Alexandria Venture Investments
Delos Capital
Eli Lilly and Company
Forbion
Johnson & Johnson Innovation – JJDC

Investments

$150M2026-08-13MapLight TherapeuticsForbion, Life Sciences at Goldman Sachs Alternatives, Deep Track Capital, Avego BioScience Capital
$50M2026-01-27TRexBioEli Lilly and Company, SV Health Investors, Johnson & Johnson Innovation – JJDC, Pfizer Ventures, Alexandria Venture Investments, Polaris Partners, Delos Capital, Avego BioScience Capital, Janus Henderson Investors
$200M2025-07-28MapLight TherapeuticsForbion, Life Sciences at Goldman Sachs Alternatives, Novo Holdings, 5am Ventures, Blue Owl Healthcare Opportunities, Pivotal bioVenture Partners, Avego BioScience Capital
$84M2024-11-13TRexBioDelos Capital, Eli Lilly and Company, SV Health Investors, Johnson & Johnson Innovation – JJDC, Pfizer Ventures, Alexandria Venture Investments, Polaris Partners, Avego BioScience Capital, Agent Capital